ABOUT CHINA FOCUS @BWB
China has embraced a vigorously growing healthcare market in the past decade. Ever since joining ICH in 2017, China has seen increased clinical trials and accelerated new drug and device approval. For biotech and MedTech companies outside of China, you need to find the right partners and the right resources to bring your products to China, in order to adapt to the difference in culture, regulation, reimbursement, etc. In the meantime, Chinese biotechs are actively seeking global market entry opportunities and overseas partners.
China Focus @BWB is designed to provide a meaningful platform to inform, inspire, and foster cross-border partnership in life science and healthcare.
- Investors (VC, PE, investment bank, etc.)
- Life science innovators and entrepreneurs
- Biotech & big pharma
- Medtech (device and diagnostics) manufacturers and distributors
- Service providers (law firm, financial advisory, regulatory consulting, CRO, CDMO, etc.)
- Healthcare providers
- Regulatory reforms in China and the impact on cross-border partnership
- Chinese biopharma’s strategies to meet the domestic and global needs for innovation
- Join forces in a global battle against cancer
- Cell and gene therapy – opportunities for collaboration
- Winning recipes in a competitive landscape of licensing
- Learn about Chinese life science and healthcare industry
- Hear about the latest Chinese regulatory reforms and implications
- Meet with the decision makers in the industry
- Initiate business conversations that otherwise difficult to start
Attendees
%
Executive Level Attendees
Chinese Companies and Investors
One-to-one meetings
TO
EXPECT
complimentary registration
Download Sample Attendee List from past China Focus events
Download Program from past China Focus events
Katherine Andersen
Head of U.S. Life Science & Healthcare Relationship Banking
Silicon Valley Bank
Laura Benjamin
President and CEO
Oncologie
Wei (William) Cao
Chairman and CEO
Gracell Biotechnologies
Miguel Forte
CEO - Zelluna Immunotherapy
CCO - the International Society for Cell and Gene Therapy
Gordon Freeman
Professor of Medical Oncology
Dana-Farber Cancer Center/Harvard Medical School
Xi-Yong (Sean) Fu
President
Luye Boston R&D LLC
Lei (Geffrey) Gao
Executive VP/Deputy General Manager
Harbin Pharma
Jiawen Han
Head of Business Development (USA)
Qilu Pharmaceutical
Jie (Jay) Liu
Managing Director
Torreya Partners
Harvey Lodish
Founding Member and Professor
Whitehead Institute of Biomedical Research/MIT
Travis McCready
President and CEO
Massachusetts Life Sciences Center
Hua Mu
Chief Medical Officer
Simcere Pharmaceutical Group
Samuel Murphy
VP and Head of International BD
Salubris Pharmaceuticals
Konstantin Poukalov
Perceptive Advisors
Anna Vardanyan
Executive Director, Business Development and Alliance Management
Everest Medicines
Danhui Wang
Founding partner
Remedeca Partners LLC
Qingxi (Charles) Wang
Executive President of International Division and Business Development, Executive Director of the Board
CSPC Pharmaceutical Group Ltd.
Jack Wu
Head of Business Development (USA)
Adlai Nortye Biopharma
Lijun Wu
CSO
Fosun Pharma US
Haishan Xiong
Senior VP Business Development
FMD K&L
Xiangbin (Shawn) Xu
Executive Director
Simcere Innovation, Inc.
Zengjun (Alex) Xu
Chief Scientist
CDE/NMPA
Mark Young
Co-founder & Managing Partner
Bridge Point Capital
Xiangyang (Sean) Zhang
CEO
Hengrui Therapeutics
Youwen (Allen) Dai
Registration, Sponsorship and Collaboration (U.S. and Europe)
Han Yan
General Inquiries
info@mybiogate.com
832-497-2220